leisure time -WSS

leisure time

author：hotspot 2025-09-03 12:02:52 - browse：1688

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

WSS

Pregnancy ages women, but effects reverse after delivery

Astellas still sees hope in its gene therapy after four deaths

Bring on the sabbaticals for nurses

Biotech investment managers search for lucrative opportunities

Bring on the sabbaticals for nurses

U.K. officials, researchers try to ease path for bespoke genetic treatments

hotspot

leisure time

focus

Continuity nursing helped my family in our darkest PICU moments

PBM reforms clear House panel

As demand for Covid shots wanes, Moderna seeks its next success

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

NYU radiologists take on the challenge of expensive MRI machines

Continuity nursing helped my family in our darkest PICU moments

Diabetes management: Digital health tools fall short, study says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

CRISPR pioneers react to Casgevy, first gene

entertainment

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Biotech investment managers search for lucrative opportunities

Morphosys mixed study results for blood cancer drug

Ransomware attacks on hospitals: Study outlines patient impact

Congress must reauthorize a committee to support older Americans

hotspot

Wikipedia

hotspot

entertainment